Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
AlzeCure Pharma
ALZCURAlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden. Address: HAelsovAegen 7, Huddinge, Sweden, 141 57
Analytics
Preço Alvo de Wall Street
107.27 SEKRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave ALZCUR
Análise de Dividendos ALZCUR
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos ALZCUR
Avaliação de ações ALZCUR
Relatório ALZCUR
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |